help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ozaki, H.
Right arrow Articles by Campochiaro, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ozaki, H.
Right arrow Articles by Campochiaro, P. A.
(American Journal of Pathology. 2000;156:697-707.)
© 2000 American Society for Investigative Pathology

Regular Articles

Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely Prevent Retinal Neovascularization

Hiroaki Ozaki*, Man-Seong Seo*, Keiko Ozaki*, Haruhiko Yamada*, Eri Yamada*, Naoyuki Okamoto*, Francesco Hofmann{dagger}, Jeanette M. Wood{dagger} and Peter A. Campochiaro*

From the Departments of Ophthalmology and Neuroscience,*
The Johns Hopkins University School of Medicine, Baltimore, Maryland; and The Division of Oncology Research,{dagger}
Pharmaceutical Division, Research and Development, Novartis Ltd Pharmaceuticals, Inc., Basel, Switzerland

Retinal vasculogenesis and ischemic retinopathies provide good model systems for study of vascular development and neovascularization (NV), respectively. Vascular endothelial cell growth factor (VEGF) has been implicated in the pathogenesis of retinal vasculogenesis and in the development of retinal NV in ischemic retinopathies. However, insulin-like growth factor-I and possibly other growth factors also participate in the development of retinal NV and intraocular injections of VEGF antagonists only partially inhibit retinal NV. One possible conclusion from these studies is that it is necessary to block other growth factors in addition to VEGF to achieve complete inhibition of retinal NV. We recently demonstrated that a partially selective kinase inhibitor, PKC412, that blocks phosphorylation by VEGF and platelet-derived growth factor (PDGF) receptors and several isoforms of protein kinase C (PKC), completely inhibits retinal NV. In this study, we have used three additional selective kinase inhibitors with different selectivity profiles to explore the signaling pathways involved in retinal NV. PTK787, a drug that blocks phosphorylation by VEGF and PDGF receptors, but not PKC, completely inhibited retinal NV in murine oxygen-induced ischemic retinopathy and partially inhibited retinal vascularization during development. CGP 57148 and CGP 53716, two drugs that block phosphorylation by PDGF receptors, but not VEGF receptors, had no significant effect on retinal NV. These data and our previously published study suggest that regardless of contributions by other growth factors, VEGF signaling plays a critical role in the pathogenesis of retinal NV. Inhibition of VEGF receptor kinase activity completely blocks retinal NV and is an excellent target for treatment of proliferative diabetic retinopathy and other ischemic retinopathies.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Ikeda, R. Nakano, M. Uraoka, Y. Nakagawa, M. Koide, A. Katsume, K. Minamino, E. Yamada, H. Yamada, T. Quertermous, et al.
Identification of ARIA regulating endothelial apoptosis and angiogenesis by modulating proteasomal degradation of cIAP-1 and cIAP-2
PNAS, May 19, 2009; 106(20): 8227 - 8232.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
A. Higuchi, K. Ohashi, S. Kihara, K. Walsh, and N. Ouchi
Adiponectin Suppresses Pathological Microvessel Formation in Retina Through Modulation of Tumor Necrosis Factor-{alpha} Expression
Circ. Res., May 8, 2009; 104(9): 1058 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Card Surg AdultHome page
K. A. Horvath and Y. Zhou
Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow
Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752.
[Full Text]

Home page
 IOVSHome page
H. Ameri, G. J. Chader, J.-G. Kim, S. R. Sadda, N. A. Rao, and M. S. Humayun
The Effects of Intravitreous Bevacizumab on Retinal Neovascular Membrane and Normal Capillaries in Rabbits
Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5708 - 5715.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Hollborn, C. Stathopoulos, A. Steffen, P. Wiedemann, L. Kohen, and A. Bringmann
Positive Feedback Regulation between MMP-9 and VEGF in Human RPE Cells
Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4360 - 4367.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
I. Idris and R. Donnelly
Protein kinase C {beta} inhibition: a novel therapeutic strategy for diabetic microangiopathy
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 172 - 178.
[Abstract] [PDF]

Home page
 Br. J. Ophthalmol.Home page
R B Bhisitkul
Vascular endothelial growth factor biology: clinical implications for ocular treatments.
Br. J. Ophthalmol., December 1, 2006; 90(12): 1542 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
S. X Zhang, J. J Wang, G. Gao, K. Parke, and J.-x. Ma
Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.
J. Mol. Endocrinol., August 1, 2006; 37(1): 1 - 12.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Banin, M. I. Dorrell, E. Aguilar, M. R. Ritter, C. M. Aderman, A. C. H. Smith, J. Friedlander, and M. Friedlander
T2-TrpRS Inhibits Preretinal Neovascularization and Enhances Physiological Vascular Regrowth in OIR as Assessed by a New Method of Quantification
Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2125 - 2134.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. D. Modanlou, Z. Gharraee, J. Hasan, J. Waltzman, S. Nageotte, and K. D. A. Beharry
Ontogeny of VEGF, IGF-I, and GH in Neonatal Rat Serum, Vitreous Fluid, and Retina from Birth to Weaning
Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 738 - 744.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. P. Aiello
Angiogenic Pathways in Diabetic Retinopathy
N. Engl. J. Med., August 25, 2005; 353(8): 839 - 841.
[Full Text] [PDF]

Home page
 DiabetesHome page
The PKC-DRS Study Group
The Effect of Ruboxistaurin on Visual Loss in Patients With Moderately Severe to Very Severe Nonproliferative Diabetic Retinopathy: Initial Results of the Protein Kinase C {beta} Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial
Diabetes, July 1, 2005; 54(7): 2188 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. O. Zamora, M. H. Davies, S. R. Planck, J. T. Rosenbaum, and M. R. Powers
Soluble Forms of EphrinB2 and EphB4 Reduce Retinal Neovascularization in a Model of Proliferative Retinopathy
Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 2175 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Sarlos and J. L. Wilkinson-Berka
The Renin-Angiotensin System and the Developing Retinal Vasculature
Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1069 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
T. Tammela, B. Enholm, K. Alitalo, and K. Paavonen
The biology of vascular endothelial growth factors
Cardiovasc Res, February 15, 2005; 65(3): 550 - 563.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. V. Ljubimov, S. Caballero, A. M. Aoki, L. A. Pinna, M. B. Grant, and R. Castellon
Involvement of Protein Kinase CK2 in Angiogenesis and Retinal Neovascularization
Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4583 - 4591.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn
Vascular Endothelial Growth Factor and Angiogenesis
Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
A. Das, N. Boyd, T. R. Jones, N. Talarico, and P. G. McGuire
Inhibition of Choroidal Neovascularization by a Peptide Inhibitor of the Urokinase Plasminogen Activator and Receptor System in a Mouse Model
Arch Ophthalmol, December 1, 2004; 122(12): 1844 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. S. Wall, R. L. Gendron, W. V. Good, E. Miskiewicz, M. Woodland, K. Leblanc, and H. Paradis
Conditional Knockdown of Tubedown-1 in Endothelial Cells Leads to Neovascular Retinopathy
Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3704 - 3712.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev., August 1, 2004; 25(4): 581 - 611.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. Lundkvist, A. Reichenbach, C. Betsholtz, P. Carmeliet, H. Wolburg, and M. Pekny
Under stress, the absence of intermediate filaments from Muller cells in the retina has structural and functional consequences
J. Cell Sci., July 15, 2004; 117(16): 3481 - 3488.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. W. I. Cooke, J. A. Drury, R. Mountford, and D. Clark
Genetic Polymorphisms and Retinopathy of Prematurity
Invest. Ophthalmol. Vis. Sci., June 1, 2004; 45(6): 1712 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Patel, L. Sun, D. Moshinsky, H. Chen, K. M. Leahy, P. Le, K. G. Moss, X. Wang, A. Rice, D. Tam, et al.
A Selective and Oral Small Molecule Inhibitor of Vascular Epithelial Growth Factor Receptor (VEGFR)-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 838 - 845.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. Ishida, T. Usui, K. Yamashiro, Y. Kaji, S. Amano, Y. Ogura, T. Hida, Y. Oguchi, J. Ambati, J. W. Miller, et al.
VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization
J. Exp. Med., August 4, 2003; 198(3): 483 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Khamaisi, B. F. Schrijvers, A. S. De Vriese, I. Raz, and A. Flyvbjerg
The emerging role of VEGF in diabetic kidney disease
Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1427 - 1430.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Khamaisi, B. F. Schrijvers, A. S. De Vriese, I. Raz, and A. Flyvbjerg
The emerging role of VEGF in diabetic kidney disease
Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1427 - 1430.
[Full Text]

Home page
 IOVSHome page
P. G. McGuire, T. R. Jones, N. Talarico, E. Warren, and A. Das
The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by A6 Suggests a New Therapeutic Target
Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2736 - 2742.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Le Jan, C. Amy, A. Cazes, C. Monnot, N. Lamande, J. Favier, J. Philippe, M. Sibony, J.-M. Gasc, P. Corvol, et al.
Angiopoietin-Like 4 Is a Proangiogenic Factor Produced during Ischemia and in Conventional Renal Cell Carcinoma
Am. J. Pathol., May 1, 2003; 162(5): 1521 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Hangai, N. Kitaya, J. Xu, C. K. Chan, J. J. Kim, Z. Werb, S. J. Ryan, and P. C. Brooks
Matrix Metalloproteinase-9-Dependent Exposure of a Cryptic Migratory Control Site in Collagen is Required before Retinal Angiogenesis
Am. J. Pathol., October 1, 2002; 161(4): 1429 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
S R Boyd, D Tan, C Bunce, A Gittos, M H Neale, J L Hungerford, S Charnock-Jones, and I A Cree
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window
Br. J. Ophthalmol., April 1, 2002; 86(4): 448 - 452.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. J. Duh, H. S. Yang, I. Suzuma, M. Miyagi, E. Youngman, K. Mori, M. Katai, L. Yan, K. Suzuma, K. West, et al.
Pigment Epithelium-Derived Factor Suppresses Ischemia-Induced Retinal Neovascularization and VEGF-Induced Migration and Growth
Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 821 - 829.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Griggs, J. N. Skepper, G. A. Smith, K. M. Brindle, J. C. Metcalfe, and R. Hesketh
Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4
Am. J. Pathol., March 1, 2002; 160(3): 1097 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. S. McLeod, M. Taomoto, J. Cao, Z. Zhu, L. Witte, and G. A. Lutty
Localization of VEGF Receptor-2 (KDR/Flk-1) and Effects of Blocking It in Oxygen-Induced Retinopathy
Invest. Ophthalmol. Vis. Sci., February 1, 2002; 43(2): 474 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
J.N. UPALAKALIN, I. HEMO, C. DEHIO, E. KESHET, and L.E. BENJAMIN
Survival Mechanisms of VEGF and PlGF during Microvascular Remodeling
Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 181 - 188.
[Abstract] [PDF]

Home page
 IOVSHome page
R. L. Gendron, W. V. Good, L. C. Adams, and H. Paradis
Suppressed Expression of Tubedown-1 in Retinal Neovascularization of Proliferative Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci., November 1, 2001; 42(12): 3000 - 3007.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. E. Epstein, R. Kornowski, S. Fuchs, and H. F. Dvorak
Angiogenesis Therapy : Amidst the Hype, the Neglected Potential for Serious Side Effects
Circulation, July 3, 2001; 104(1): 115 - 119.
[Full Text] [PDF]

Home page
 IOVSHome page
M. Hangai, T. Murata, N. Miyawaki, C. Spee, J. I. Lim, S. He, D. R. Hinton, and S. J. Ryan
Angiopoietin-1 Upregulation by Vascular Endothelial Growth Factor in Human Retinal Pigment Epithelial Cells
Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1617 - 1625.
[Abstract] [Full Text]

Home page
 Arch OphthalmolHome page
T. Murata, Y. Hata, T. Ishibashi, S. Kim, W. A. Hsueh, R. E. Law, and D. R. Hinton
Response of Experimental Retinal Neovascularization to Thiazolidinediones
Arch Ophthalmol, May 1, 2001; 119(5): 709 - 717.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Hellstrom, C. Perruzzi, M. Ju, E. Engström, A.-L. Hård, J.-L. Liu, K. Albertsson-Wikland, B. Carlsson, A. Niklasson, L. Sjödell, et al.
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity
PNAS, May 1, 2001; (2001) 101113998.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
L. E. Benjamin
Glucose, VEGF-A, and Diabetic Complications
Am. J. Pathol., April 1, 2001; 158(4): 1181 - 1184.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, March 22, 2001; (2001) 81615298.
[Abstract] [Full Text]

Home page
 Br. J. Ophthalmol.Home page
G B ARDEN
The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment
Br. J. Ophthalmol., March 1, 2001; 85(3): 366 - 370.
[Full Text]

Home page
 Cardiovasc ResHome page
S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski
Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards
Cardiovasc Res, February 16, 2001; 49(3): 532 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Stellmach, S. E. Crawford, W. Zhou, and N. Bouck
Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor
PNAS, January 23, 2001; (2001) 31252398.
[Abstract] [Full Text]

Home page
 HypertensionHome page
C. J. Moravski, D. J. Kelly, M. E. Cooper, R. E. Gilbert, J. F. Bertram, S. Shahinfar, S. L. Skinner, and J. L. Wilkinson-Berka
Retinal Neovascularization Is Prevented by Blockade of the Renin-Angiotensin System
Hypertension, December 1, 2000; 36(6): 1099 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O’Reilly, et al.
PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration
Cancer Res., April 1, 2000; 60(8): 2178 - 2189.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Stellmach, S. E. Crawford, W. Zhou, and N. Bouck
Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor
PNAS, February 27, 2001; 98(5): 2593 - 2597.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al.
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
PNAS, April 10, 2001; 98(8): 4605 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Hellstrom, C. Perruzzi, M. Ju, E. Engstrom, A.-L. Hard, J.-L. Liu, K. Albertsson-Wikland, B. Carlsson, A. Niklasson, L. Sjodell, et al.
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity
PNAS, May 8, 2001; 98(10): 5804 - 5808.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.